（编辑 丛可心） 证券日报网讯 12月19日晚间，益诺思发布公告称，股东上海翱鹏企业管理中心（有限合伙）计划自 2026年1月14日至2026年4月13日，通过集中竞价方式减持不超过1，409，796股，占公司总股本 1.00%，减持股份来源为IPO前取得。 ...

公告显示，翱鹏合伙为公司员工持股平台，公司部分董事、高级管理人员及核心技术人员通过该员工持 股平台间接持有公司股份。翱鹏合伙持有益诺思股份1741.24万股，占公司总股本的12.35%。 北京商报讯（记者 丁宁）12月19日晚间，益诺思（688710）发布公告称，上海翱鹏企业管理中心（有 限合伙）（以下简称"翱鹏合伙"）计划自公告披露之日起15个交易日后的3个月内，通过集中竞价交易 方式减持其所持有的公司股份数量不超过140.98万股，占公司总股本的比例不超过1%。 ...

Core Viewpoint - Yinos (688710.SH) announced a share reduction plan by its shareholder, Aopeng Partnership, which will take place within a specified timeframe [1] Group 1: Share Reduction Plan - Aopeng Partnership plans to reduce its holdings by no more than 1.40 million shares, which represents up to 1.00% of the company's total share capital [1] - The reduction will occur through centralized bidding transactions starting 15 trading days after the announcement [1] - The total number of shares reduced within any continuous 90-day period will not exceed 1.00% of the company's total shares [1]

Core Viewpoint - Yinos (688710.SH) announced that the Aopeng Partnership Plan will reduce its shareholding in the company by up to 1.4 million shares, representing no more than 1% of the total share capital, within three months after the announcement [1] Group 1 - The Aopeng Partnership is an employee stock ownership platform for the company [1] - Some of the company's directors, senior management, and core technical personnel hold shares indirectly through this employee stock ownership platform [1] - The reduction of shares will be conducted through centralized bidding and will not exceed 1% of the total shares within any consecutive 90-day period [1]

翱鹏合伙为公司员工持股平台，公司部分董事、高级管理人员及核心技术人员通过该员工持股平台间接 持有公司股份。 益诺思(688710.SH)发布公告，翱鹏合伙计划自公告披露之日起15个交易日后的3个月内，通过集中竞价 交易方式减持其所持有的公司股份数量不超过140.98万股，占公司总股本的比例不超过1%，且在任意 连续90个自然日内，减持的股份总数不超过公司股份总数的1%。 ...

股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 证券代码：688710 证券简称：益诺思 公告编号：2025-045 上海益诺思生物技术股份有限公司 重要内容提示： 股东持股的基本情况 截至本公告披露日，上海翱鹏企业管理中心（有限合伙）（以下简称"翱 鹏合伙"）持有上海益诺思生物技术股份有限公司（以下简称"公司"）17,412,396 股，占公司总股本的 12.35%。翱鹏合伙为公司员工持股平台，公司部分董事、 高级管理人员及核心技术人员通过该员工持股平台间接持有公司股份。 减持计划的主要内容 翱鹏合伙计划自本公告披露之日起 15 个交易日后的 3 个月内，通过集中竞 价交易方式减持其所持有的公司股份数量不超过 1,409,796 股，占公司总股本的 比例不超过 1.00%，且在任意连续 90 个自然日内，减持的股份总数不超过公司 股份总数的 1.00%。减持价格按市场价格确定，若在上述减持计划实施期间，公 司发生派发红利、送红股、转增股本、增发新股或配股等股本变动、除权除息事 项，则上述 ...

益诺思公告，持股1741.24万股、占12.35%的股东上海翱鹏企业管理中心（有限合伙）计划自公告披露 之日起15个交易日后的3个月内，即2026年1月14日～2026年4月13日，通过集中竞价方式减持不超过 140.98万股，占公司总股本的1.00%，并在任意连续90个自然日内减持比例不超过1.00%；减持价格按届 时市场价格确定。 ...

Company Overview - Yinos Bio is located in the China (Shanghai) Pilot Free Trade Zone and was established on May 12, 2010. The company specializes in providing non-clinical research services in the biopharmaceutical sector, primarily as a Contract Research Organization (CRO) [1] - The company's revenue composition is as follows: non-clinical services account for 96.31%, clinical services for 3.42%, and other services for 0.27% [1] Stock Performance - As of December 18, Yinos Bio's stock price increased by 2.03%, reaching 51.36 CNY per share, with a total market capitalization of 7.241 billion CNY [1] - Year-to-date, the stock price has risen by 45.95%, with a 19.16% increase over the last five trading days, a 10.64% increase over the last 20 days, and a 9.63% increase over the last 60 days [1] Financial Performance - For the period from January to September 2025, Yinos Bio reported a revenue of 571 million CNY, representing a year-on-year decrease of 35.33%. The net profit attributable to shareholders was -14.7881 million CNY, a decline of 111.14% compared to the previous year [2] Shareholder Information - As of September 30, the number of shareholders for Yinos Bio was 4,849, a decrease of 9.97% from the previous period. The average number of circulating shares per person increased by 257.28% to 18,703 shares [2] - The company has distributed a total of 45.1135 million CNY in dividends since its A-share listing [3] - Notable changes in institutional holdings include new entries from Huatai-PineBridge Healthcare Mixed Fund and Huaxia Stable Growth Mixed Fund among the top ten circulating shareholders [3]

Core Viewpoint - Shanghai Yinos Biotechnology Co., Ltd. has been awarded the "2025 Most Socially Responsible Listed Company Award" for its outstanding practices in social responsibility and professional service capabilities, highlighting its deep accumulation and core value in the CRO professional segment [1][3] Company Overview - Yinos is a comprehensive R&D service (CRO) company specializing in non-clinical research services for biomedicine, adhering to the core values of "science-led, quality-first, integrity, and win-win cooperation" [3] - The company focuses on major national biomedicine development needs and plays a significant role in drug evaluation services, contributing to the high-quality development of the biomedicine industry [3] Business Performance - In Q3 2025, Yinos achieved operating revenue of 195 million yuan, a quarter-on-quarter increase of 17.71%, maintaining a steady growth trend [4] - The company saw a 29.37% year-on-year increase in new order amounts, with significant growth in new drug clinical trial applications (IND) and new drug marketing applications (NDA), which rose by 30.71% and 23.06% respectively [4] Market Position and Strategy - Yinos is positioned as a leading enterprise in the CRO industry, benefiting from a high-growth cycle and possessing technical advantages that meet high-end demand across the entire service chain [4] - The company has established a non-clinical drug metabolism platform compliant with ICH, FDA, and NMPA standards, enhancing its capabilities in radiolabeled isotopes and imaging evaluation research [4] Innovation and International Expansion - Yinos is continuously advancing frontier technologies, particularly in small nucleic acid drugs and CAR-T cell therapy, establishing a comprehensive technical service matrix [5][6] - The company has expanded its international market presence, with significant growth in new order amounts from overseas, enhancing its brand influence and recognition [6] Future Outlook - The award received is not only a recognition of past achievements but also an expectation for future development, as CRO companies play an increasingly important role in new drug development [6] - Yinos aims to leverage this award to strengthen its professional advantages while actively fulfilling social responsibilities, contributing to the high-quality development of China's biomedicine industry [6]

证券之星消息，12月12日医疗服务板块较上一交易日上涨1.17%，益诺思领涨。当日上证指数报收于 3889.35，上涨0.41%。深证成指报收于13258.33，上涨0.84%。医疗服务板块个股涨跌见下表： 从资金流向上来看，当日医疗服务板块主力资金净流出2.4亿元，游资资金净流入1.35亿元，散户资金净 流入1.05亿元。医疗服务板块个股资金流向见下表： | 代码 | 名称 | | 主力净流入 (元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 603127 | 昭衍新药 | | 5.03 Z | 30.20% | -2.10 Z | -12.62% | -2.93 Z | -17.58% | | 300015 | 爰尔眼科 | | 5317.94万 | 8.82% | -6481.96万 | -10.74% | 1164.02万 | 1.93% | | 300759 | 康龙化成 | | 3575.66万 | 3.45% | -2598 ...